** Shares of drug developer Disc Medicine rise ~28.6% to $60.60, highest since March

** Co says the FDA gave positive feedback supporting the design of a trial that will evaluate its genetic disorder drug bitopertin

** Bitopertin is being developed for the treatment of Erythropoietic protoporphyria $(EPP.UK)$, a rare inherited metabolic disorder

** IRON says the drug has potential for FDA's accelerated approval based on existing data

** "Improved approval timelines and clarification of confirmatory trial design are significant positives to IRON shares," says BMO Capital Markets

** Stock up 15.1% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))